AroCell AB (publ) (AROC.ST)
SEK 0.38
(-4.98%)
SEK 0.38
(-4.98%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -59.29 Million SEK | -0.55% |
| 2022 | -58.97 Million SEK | -17.88% |
| 2021 | -50.02 Million SEK | -157.08% |
| 2020 | -19.45 Million SEK | -20.1% |
| 2019 | -16.2 Million SEK | 21.94% |
| 2018 | -20.75 Million SEK | -20.19% |
| 2017 | -17.27 Million SEK | -87.02% |
| 2016 | -9.23 Million SEK | -23.48% |
| 2015 | -7.47 Million SEK | -17.43% |
| 2014 | -6.36 Million SEK | -70.61% |
| 2013 | -3.73 Million SEK | -18.25% |
| 2012 | -3.15 Million SEK | 11.92% |
| 2011 | -3.58 Million SEK | -66.53% |
| 2010 | -2.15 Million SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -10.5 Million SEK | 38.7% |
| 2024 Q3 | -9.84 Million SEK | 24.61% |
| 2024 Q2 | -13.05 Million SEK | -24.26% |
| 2023 FY | -59.29 Million SEK | -0.55% |
| 2023 Q3 | -13 Million SEK | 16.06% |
| 2023 Q2 | -15.49 Million SEK | -13.36% |
| 2023 Q4 | -17.13 Million SEK | -31.78% |
| 2023 Q1 | -13.66 Million SEK | 17.24% |
| 2022 Q1 | -15.48 Million SEK | 21.38% |
| 2022 Q4 | -16.51 Million SEK | -49.15% |
| 2022 Q3 | -11.07 Million SEK | 30.38% |
| 2022 Q2 | -15.9 Million SEK | -2.68% |
| 2022 FY | -58.97 Million SEK | -17.88% |
| 2021 Q1 | -6.07 Million SEK | -1.11% |
| 2021 Q3 | -17.51 Million SEK | -160.43% |
| 2021 Q4 | -19.69 Million SEK | -12.44% |
| 2021 FY | -50.02 Million SEK | -157.08% |
| 2021 Q2 | -6.72 Million SEK | -10.66% |
| 2020 Q1 | -5.47 Million SEK | 9.28% |
| 2020 Q4 | -6.01 Million SEK | 5.63% |
| 2020 FY | -19.45 Million SEK | -20.1% |
| 2020 Q3 | -6.37 Million SEK | -2.84% |
| 2020 Q2 | -6.19 Million SEK | -13.17% |
| 2019 Q4 | -6.03 Million SEK | -34.09% |
| 2019 Q3 | -4.5 Million SEK | 8.44% |
| 2019 FY | -16.2 Million SEK | 21.94% |
| 2019 Q1 | -5.28 Million SEK | 3.22% |
| 2019 Q2 | -4.91 Million SEK | 7.04% |
| 2018 Q1 | -4.18 Million SEK | 27.41% |
| 2018 Q2 | -5.71 Million SEK | -36.59% |
| 2018 FY | -20.75 Million SEK | -20.19% |
| 2018 Q4 | -5.46 Million SEK | -1.17% |
| 2018 Q3 | -5.4 Million SEK | 5.46% |
| 2017 Q4 | -5.76 Million SEK | -56.63% |
| 2017 FY | -17.27 Million SEK | -87.02% |
| 2017 Q3 | -3.67 Million SEK | -2.0% |
| 2017 Q2 | -3.6 Million SEK | 14.65% |
| 2017 Q1 | -4.22 Million SEK | -62.63% |
| 2016 FY | -9.23 Million SEK | -23.48% |
| 2016 Q1 | -2.84 Million SEK | -75.22% |
| 2016 Q2 | -1.96 Million SEK | 30.96% |
| 2016 Q3 | -2.59 Million SEK | -32.06% |
| 2016 Q4 | -2.59 Million SEK | -0.27% |
| 2015 FY | -7.47 Million SEK | -17.43% |
| 2015 Q2 | -1.64 Million SEK | 31.56% |
| 2015 Q1 | -2.4 Million SEK | 12.93% |
| 2015 Q4 | -1.62 Million SEK | 10.44% |
| 2015 Q3 | -1.81 Million SEK | -10.16% |
| 2014 Q1 | -1.11 Million SEK | 26.97% |
| 2014 Q4 | -2.75 Million SEK | -159.29% |
| 2014 FY | -6.36 Million SEK | -70.61% |
| 2014 Q3 | -1.06 Million SEK | 25.49% |
| 2014 Q2 | -1.42 Million SEK | -27.73% |
| 2013 FY | -3.73 Million SEK | -18.25% |
| 2013 Q1 | -868 Thousand SEK | 11.88% |
| 2013 Q4 | -1.53 Million SEK | -239.45% |
| 2013 Q3 | -451 Thousand SEK | 48.92% |
| 2013 Q2 | -883 Thousand SEK | -1.73% |
| 2012 Q1 | -721 Thousand SEK | 37.41% |
| 2012 Q2 | -904 Thousand SEK | -25.38% |
| 2012 Q4 | -985 Thousand SEK | -80.07% |
| 2012 Q3 | -547 Thousand SEK | 39.49% |
| 2012 FY | -3.15 Million SEK | 11.92% |
| 2011 Q2 | -1.23 Million SEK | -78.02% |
| 2011 Q3 | -497 Thousand SEK | 59.89% |
| 2011 FY | -3.58 Million SEK | -66.53% |
| 2011 Q1 | -696 Thousand SEK | -16.73% |
| 2011 Q4 | -1.15 Million SEK | -131.79% |
| 2010 Q3 | -581 Thousand SEK | -3.57% |
| 2010 Q2 | -561 Thousand SEK | 0.0% |
| 2010 Q4 | -596.23 Thousand SEK | -2.62% |
| 2010 FY | -2.15 Million SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Devyser Diagnostics AB (publ) | -53.6 Million SEK | -10.629% |
| Immunovia AB (publ) | -309.43 Million SEK | 80.837% |
| Prostatype Genomics AB (publ) | -41.43 Million SEK | -43.108% |
| SenzaGen AB | -22.09 Million SEK | -168.349% |
| Spermosens AB | -12.2 Million SEK | -385.961% |